<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BRN</journal-id>
<journal-id journal-id-type="hwp">spbrn</journal-id>
<journal-id journal-id-type="nlm-ta">Biol Res Nurs</journal-id>
<journal-title>Biological Research For Nursing</journal-title>
<issn pub-type="ppub">1099-8004</issn>
<issn pub-type="epub">1552-4175</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1099800411403918</article-id>
<article-id pub-id-type="publisher-id">10.1177_1099800411403918</article-id>
<title-group>
<article-title>The 6-Min Walk Test</article-title>
<subtitle>Is It an Effective Method for Evaluating Heart Failure Therapies?</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Vuckovic</surname>
<given-names>Karen M.</given-names>
</name>
<degrees>RN, MS, ACNS, CCRN</degrees>
<xref ref-type="aff" rid="aff1-1099800411403918">1</xref>
<xref ref-type="corresp" rid="corresp1-1099800411403918"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fink</surname>
<given-names>Anne M.</given-names>
</name>
<degrees>RN, MS, CCRN</degrees>
<xref ref-type="aff" rid="aff1-1099800411403918">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1099800411403918"><label>1</label>Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago, Chicago, IL, USA</aff>
<author-notes>
<corresp id="corresp1-1099800411403918">Karen M. Vuckovic, RN, MS, ACNS, CCRN, Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago, 845 South Damen Avenue, Chicago, IL 60612, USA Email: <email>Vuckovic@uic.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>14</volume>
<issue>2</issue>
<fpage>147</fpage>
<lpage>159</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The 6-min walk (6MW) is a self-paced test for measuring functional capacity. Lower 6MW distances have been associated with adverse outcomes in patients with heart failure. The purpose of this article is to describe the history of the 6MW test and to evaluate its reliability, validity, and predictive value as well as the responsiveness of the test to therapies. In the literature we reviewed, reliability was affected by several factors including learning effects and protocol deviations. The 6MW distance was moderately correlated with peak oxygen consumption derived from cardiopulmonary exercise stress testing. In some studies the 6MW distance was predictive of hospitalization and mortality. In pharmacological and cardiac resynchronization trials the 6MW distance did not consistently detect clinical improvements. Despite limitations, the 6MW test is a viable alternative to stress testing for objectively evaluating functional capacity in some settings. We provide recommendations for using the 6MW test in future studies.</p>
</abstract>
<kwd-group>
<kwd>heart failure</kwd>
<kwd>6-min walk test</kwd>
<kwd>functional capacity</kwd>
<kwd>measurement</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>In patients with heart failure (HF), a reduction in functional capacity is associated with adverse outcomes, such as increased mortality (<xref ref-type="bibr" rid="bibr1-1099800411403918">Alahdab, Mansour, Napan, &amp; Stamos, 2009</xref>). Valid and reliable measures of functional capacity are increasingly important, as HF incidence and prevalence continue to rise, and patients are living longer with HF (<xref ref-type="bibr" rid="bibr46-1099800411403918">Lloyd-Jones et al., 2010</xref>; <xref ref-type="bibr" rid="bibr64-1099800411403918">Schocken et al., 2008</xref>). In the United States, 5.8 million people have HF (<xref ref-type="bibr" rid="bibr46-1099800411403918">Lloyd-Jones et al., 2010</xref>). The criterion method, or gold standard, for measuring functional capacity is cardiopulmonary exercise stress testing (CPET), during which an investigator measures a patient’s peak oxygen consumption (peak VO<sub>2</sub>; <xref ref-type="bibr" rid="bibr6-1099800411403918">Balady et al., 2010</xref>; <xref ref-type="bibr" rid="bibr25-1099800411403918">Fleg et al., 2000</xref>). The 6-min walk (6MW) test is an attractive alternative to CPET because it does not require specialized equipment and can be conducted easily in most settings. Importantly, investigators have found that changes in the 6MW distance correlate with worsening HF and mortality (<xref ref-type="bibr" rid="bibr1-1099800411403918">Alahdab et al., 2009</xref>; <xref ref-type="bibr" rid="bibr9-1099800411403918">Bittner et al., 1993</xref>; <xref ref-type="bibr" rid="bibr62-1099800411403918">Rostagno et al., 2003</xref>). Although the 6MW test has been used in many studies, including randomized clinical trials, there is still a need to specifically evaluate the 6MW test for HF research. In this article, we describe the history of the 6MW test in HF and explore the literature to evaluate the reliability, validity, and predictive value of the test as well as its responsiveness to HF therapies.</p>
<sec id="section1-1099800411403918">
<title>History of the 6MW Test in HF</title>
<p>Investigators and clinicians use several methods to measure functional capacity (<xref ref-type="table" rid="table1-1099800411403918">Table 1</xref>
), including the 6MW test. <xref ref-type="bibr" rid="bibr15-1099800411403918">Butland, Pang, Gross, Woodcock, and Geddes (1982)</xref> demonstrated that the 6MW test was a reproducible measure of exercise intolerance and had discriminative validity in patients with chronic respiratory disease. Guyatt and colleagues (1985) reported the early use of the 6MW test in HF, as they examined the effects of repeated testing and subject encouragement on the distance walked as well as the relationship between 6MW distances and metabolic calculations from bicycle ergometry stress testing (a gold standard). The 43 patients in their study had either chronic lung disease (<italic>n</italic> = 25) or HF (<italic>n</italic> = 18), and all reported a history of dyspnea or fatigue with daily activities. Patients in the HF group had left ventricular dysfunction, but the authors did not report the mean ejection fraction (EF). These patients underwent additional assessment of functional status using the New York Heart Association classification system (NYHA class; <xref ref-type="bibr" rid="bibr18-1099800411403918">Criteria Committee of the New York Heart Association, 1994</xref>; <xref ref-type="bibr" rid="bibr44-1099800411403918">Lindenfeld et al., 2010</xref>) and the Specific Activity Scale (SAS; <xref ref-type="bibr" rid="bibr28-1099800411403918">Goldman, Hashimoto, Cook, &amp; Loscalzo, 1981</xref>). As described in <xref ref-type="table" rid="table1-1099800411403918">Table 1</xref>, subjects for both the NYHA and SAS are grouped into classes, from I to IV, with higher class indicating poorer functional capacity. Guyatt and colleagues (1985) found that repeated testing of the 6MW and encouragement from the investigators were associated with significant increases in the distance walked in both the pulmonary disease and HF groups. Although the authors did not report the specific parameters measured during cycle ergometery, they did state that the 6MW distances were significantly correlated (<italic>r</italic> = .42; <italic>p</italic> &lt; .001) with the cardiometabolic calculations in both groups. For the patients with HF, the 6MW distance was inversely correlated (<italic>r</italic> = –.37; <italic>p</italic> = .001) with SAS scores, meaning that patients in higher SAS classes (patients who cannot perform activities requiring higher energy expenditure without symptoms) walked shorter distances. The authors found no statistically significant relationship, however, between the 6MW distance and NYHA class (<italic>r</italic> = –.45; <italic>p</italic> = .058). Despite the small sample size and the moderate correlations found between the 6MW test and both the cycle ergometery measures and the SAS, the investigators suggested that the 6MW test could be a useful method for future studies, and their findings were instrumental in designing 6MW protocols.</p>
<table-wrap id="table1-1099800411403918" position="float">
<label>Table 1.</label>
<caption>
<p>Methods to Measure Functional Capacity and Correlation to 6-Min Walk (6MW) Test Distance in Heart Failure (HF) Studies</p>
</caption>
<graphic alternate-form-of="table1-1099800411403918" xlink:href="10.1177_1099800411403918-table1.tif"/>
<table>
<thead>
<tr>
<th>Functional Test</th>
<th>Description</th>
<th>Strengths and Limitations</th>
<th>Study in HF Population</th>
<th align="center">Correlation With 6MW Distance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stair climbing</td>
<td>
<list list-type="simple">
<list-item>
<p>Self paced.</p>
</list-item>
<list-item>
<p>Subjects climb stairs until they reach exhaustion or experience dyspnea, leg fatigue, or chest pain.</p>
</list-item>
<list-item>
<p>A physician or nurse is present during the test to assess symptoms.</p>
</list-item>
<list-item>
<p>Observer uses encouragement.</p>
</list-item>
<list-item>
<p>Score: number of steps climbed and the time taken to complete the test are recorded.</p>
</list-item>
</list>
</td>
<td>
<list list-type="simple">
<list-item>
<p>Strengths: Anaerobic exercise; familiar activity.</p>
</list-item>
<list-item>
<p>Limitations: Energy expenditure exceeds amount required for daily activities.</p>
</list-item>
</list>
</td>
<td>
<xref ref-type="bibr" rid="bibr20-1099800411403918">Delahaye et al. (1997)</xref>; EF &lt; 35% (<italic>N</italic> = 13)</td>
<td>
<italic>r</italic> = –.82; <italic>p</italic> &lt; .001</td>
</tr>
<tr>
<td>Shuttle-walk test (SWT)</td>
<td>
<list list-type="simple">
<list-item>
<p>Similar to the 6MW test but not self paced.</p>
</list-item>
<list-item>
<p>Subject walks back and forth on a 10 m course keeping pace with external cues at increasing speed.</p>
</list-item>
<list-item>
<p>Speed is controlled by audio signal and increased every min.</p>
</list-item>
<list-item>
<p>Test ends when the subject cannot turn around in the allotted time.</p>
</list-item>
<list-item>
<p>Borg Scale used to assess dyspnea and fatigue.</p>
</list-item>
<list-item>
<p>Score: total distance walked in m.</p>
</list-item>
</list>
</td>
<td>
<list list-type="simple">
<list-item>
<p>Strengths: Distance walked correlates to peak oxygen uptake, with distance &lt;450 m associated with higher risk for cardiac events; eliminates encouragement by observer; validated in HF population.</p>
</list-item>
<list-item>
<p>Limitations: requires audiotape by the developers.</p>
</list-item>
</list>
</td>
<td>
<xref ref-type="bibr" rid="bibr50-1099800411403918">Morales et al. (1999)</xref>; EF &lt; 40% (<italic>N</italic> = 46)</td>
<td>SWT to VO<sub>2</sub><sup><xref ref-type="table-fn" rid="table-fn3-1099800411403918">b</xref></sup>; <italic>r</italic> = .83; <italic>p</italic> &lt; .001 6MW test to VO<sub>2;</sub>
<italic>r</italic> = .69; <italic>p</italic> &lt; .001</td>
</tr>
<tr>
<td>Specific Activity Scale (SAS)</td>
<td>
<list list-type="simple">
<list-item>
<p>Self administered.</p>
</list-item>
<list-item>
<p>Subject is given a list of activities associated with cardiovascular symptoms in progressive order according to METS.</p>
</list-item>
<list-item>
<p>Subject selects daily activities most likely to cause symptoms.</p>
</list-item>
<list-item>
<p>Sum of the METS is calculated.</p>
</list-item>
<list-item>
<p>Score: Class (I–IV) assigned based on the sum of the METS.</p>
</list-item>
</list>
</td>
<td>
<list list-type="simple">
<list-item>
<p>Strength: Provides an estimate of energy expenditure in metabolic units.</p>
</list-item>
<list-item>
<p>Limitations: Use is limited to patients with symptoms; requires that patients recognize their symptoms.</p>
</list-item>
</list>
</td>
<td>
<xref ref-type="bibr" rid="bibr32-1099800411403918">Guyatt et al. (1985)</xref>; Left ventricular dysfunction<sup><xref ref-type="table-fn" rid="table-fn2-1099800411403918">a</xref>
</sup>
</td>
<td>
<italic>r</italic> = –.37; <italic>p =</italic> .001</td>
</tr>
<tr>
<td>New York Heart Association Classification (NYHA)</td>
<td>
<list list-type="simple">
<list-item>
<p>Self reported.</p>
</list-item>
<list-item>
<p>Health care provider examines and interviews the patient.</p>
</list-item>
<list-item>
<p>Classified as I (no symptoms) to IV (symptoms at rest)</p>
</list-item>
<list-item>
<p>Score: Health care provider assigns a class to patient based on objective findings and patient interview.</p>
</list-item>
</list>
</td>
<td>
<list list-type="simple">
<list-item>
<p>Strength: Commonly used in research and clinical settings.</p>
</list-item>
<list-item>
<p>Limitations: Subjective and low reproducibility; interoperator agreement varies.</p>
</list-item>
</list>
</td>
<td>
<xref ref-type="bibr" rid="bibr65-1099800411403918">Shah et al. (2001)</xref>; EF ≤ 25% (<italic>n</italic> = 290)<xref ref-type="bibr" rid="bibr32-1099800411403918">Guyatt et al. (1985)</xref>; Left ventricular dysfunction</td>
<td>
<italic>r</italic> = –.468; <italic>p</italic> &lt; .001 <italic>r</italic> = –.45; <italic>p</italic> = .058</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1099800411403918">
<p>
<italic>Note:</italic> Summarized from <xref ref-type="bibr" rid="bibr4-1099800411403918">American Thoracic Society (2002)</xref>; <xref ref-type="bibr" rid="bibr14-1099800411403918">Brunelli et al. (2002)</xref>; Criteria Committee of the NYHA (1994); <xref ref-type="bibr" rid="bibr28-1099800411403918">Goldman, Hashimoto, Cook, and Loscalzo (1981)</xref>; <xref ref-type="bibr" rid="bibr50-1099800411403918">Morales et al. (1999)</xref>; <xref ref-type="bibr" rid="bibr59-1099800411403918">Raphael et al. (2007)</xref>; <xref ref-type="bibr" rid="bibr66-1099800411403918">Singh, Morgan, Scott, Walters, and Hardman (1992)</xref>. EF = ejection fraction; METS = metabolic equivalent of activity.</p>
</fn>
<fn id="table-fn2-1099800411403918">
<p>
<sup>a</sup> EF not reported in this study.</p>
</fn>
<fn id="table-fn3-1099800411403918">
<p>
<sup>b</sup> Correlated to peak VO<sub>2</sub>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Although Guyatt and colleagues (1985) did not find 6MW distances to be significantly correlated with NYHA class, other investigators later found that they were (<xref ref-type="bibr" rid="bibr7-1099800411403918">Balashov et al., 2008</xref>; <xref ref-type="bibr" rid="bibr65-1099800411403918">Shah et al., 2001</xref>). <xref ref-type="bibr" rid="bibr45-1099800411403918">Lipkin, Scriven, Crake, and Poole-Wilson (1986)</xref> found a curvilinear relationship between maximal oxygen consumption measured during treadmill exercise and the 6MW test in patients with NYHA Class II and III HF (<italic>N</italic> = 26), indicating that the patients with low-maximal oxygen consumption had the largest variance in the distance walked. The investigators concluded that the 6MW test is best suited for use in patients with moderate to severe HF.</p>
<p>Following publication of the early 6MW research from <xref ref-type="bibr" rid="bibr32-1099800411403918">Guyatt et al. (1985)</xref> and <xref ref-type="bibr" rid="bibr45-1099800411403918">Lipkin et al. (1986)</xref>, <xref ref-type="bibr" rid="bibr8-1099800411403918">Bangdiwala and colleagues (1992)</xref> incorporated the 6MW test as a physiologic measure for the first time in the design of the Studies of Left Ventricular Dysfunction (SOLVD). Bittner and colleagues (1993) analyzed the 6MW distance in a subset of patients (<italic>N</italic> = 833, age 59 years ± 12, EF 37% ± 14) enrolled in the SOLVD registry to determine the relationship between the distance walked and mortality. They found the 6MW distance to be a significant and independent predictor of mortality using multivariate analysis and controlling for age, gender, HF etiology, NYHA class, and EF. Following publication of the SOLVD findings, the 6MW test was widely used in other trials to determine the efficacy of HF therapies. For example, the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study (<italic>n</italic> = 768; <xref ref-type="bibr" rid="bibr21-1099800411403918">Demers, McKelvie, Negassa, &amp; Yusuf, 2001</xref>) and Heart Failure—A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION; <xref ref-type="bibr" rid="bibr52-1099800411403918">O’Connor et al., 2009</xref>) included the 6MW distance as an outcome measure along with other variables.</p>
</sec>
<sec id="section2-1099800411403918">
<title>What Does the 6MW Test Measure? Constructs, Terminology, and Physiology</title>
<p>Investigators have used different, yet synonymous, terms to label the construct measured by the 6MW test. Some HF researchers (<xref ref-type="bibr" rid="bibr32-1099800411403918">Guyatt et al., 1985</xref>; <xref ref-type="bibr" rid="bibr56-1099800411403918">Opasich et al., 2001</xref>; <xref ref-type="bibr" rid="bibr63-1099800411403918">Roul, German, &amp; Bareiss, 1998</xref>) use the term <italic>exercise capacity</italic>, while most, including the American Heart Association Committee on Exercise, Rehabilitation, and Prevention, prefer the term <italic>functional capacity</italic> (<xref ref-type="bibr" rid="bibr1-1099800411403918">Alahdab et al., 2009</xref>; <xref ref-type="bibr" rid="bibr5-1099800411403918">Arslan et al., 2007</xref>; <xref ref-type="bibr" rid="bibr7-1099800411403918">Balashov et al., 2008</xref>; <xref ref-type="bibr" rid="bibr11-1099800411403918">Braunschweig et al., 2009</xref>; <xref ref-type="bibr" rid="bibr16-1099800411403918">Cahalin, Mathier, Semigran, Dec, &amp; DiSalvo, 1996</xref>; <xref ref-type="bibr" rid="bibr21-1099800411403918">Demers et al., 2001</xref>; <xref ref-type="bibr" rid="bibr23-1099800411403918">Enright et al., 2003</xref>; <xref ref-type="bibr" rid="bibr25-1099800411403918">Fleg et al., 2000</xref>; <xref ref-type="bibr" rid="bibr26-1099800411403918">Frankenstein et al., 2008</xref>; <xref ref-type="bibr" rid="bibr68-1099800411403918">Zugck et al., 2000</xref>). Despite the different terminology, there is consensus that the 6MW measures submaximal exercise, which is analogous to the energy expended during activities of daily living (<xref ref-type="bibr" rid="bibr25-1099800411403918">Fleg et al., 2000</xref>). The 6MW distance is expected to correlate with peak VO<sub>2</sub> (liters/kilogram/min), the highest oxygen consumption value achieved during CPET (<xref ref-type="bibr" rid="bibr3-1099800411403918">American College of Sports Medicine, 2008</xref>). Investigators have reported significant correlations, ranging from .64 to .77, between 6MW distances and peak VO<sub>2</sub> in patients with HF (<xref ref-type="bibr" rid="bibr16-1099800411403918">Cahalin et al., 1996</xref>; <xref ref-type="bibr" rid="bibr34-1099800411403918">Hendrican et al., 2000</xref>; <xref ref-type="bibr" rid="bibr63-1099800411403918">Roul et al., 1998</xref>).</p>
<p>Although CPET allows investigators to obtain a number of important parameters related to aerobic exercise (i.e., percentage of carbon dioxide production, ratio of carbon dioxide production to oxygen consumption, minute ventilation, and ventilatory threshold; <xref ref-type="bibr" rid="bibr6-1099800411403918">Balady et al., 2010</xref>; <xref ref-type="bibr" rid="bibr25-1099800411403918">Fleg et al., 2000</xref>), limitations for using CPET include the need for specialized personnel (i.e., cardiologists and exercise physiologists) and expensive equipment (i.e., treadmill or bicycle ergometer, tight-fitting mask or mouthpiece to collect expired air; <xref ref-type="bibr" rid="bibr5-1099800411403918">Arslan et al., 2007</xref>; <xref ref-type="bibr" rid="bibr7-1099800411403918">Balashov et al., 2008</xref>). Considering these limitations, the 6MW test has been proposed as an alternative to CPET. Evidence of reliability, validity, and responsiveness to clinical changes, however, are necessary in order to advocate the 6MW as an additional or substitute measure of functional capacity. These characteristics of the 6MW test are discussed in detail later in this review.</p>
</sec>
<sec id="section3-1099800411403918">
<title>The 6MW Protocol, Scoring, and Interpretation</title>
<p>When conducting a 6MW test, the investigator asks the subject to walk back and forth along a flat 100-foot-long surface and to attempt to cover as much ground as possible; meanwhile, the investigator uses a stopwatch to measure 6 min (<xref ref-type="bibr" rid="bibr4-1099800411403918">American Thoracic Society [ATS], 2002</xref>). The test is self-paced, meaning that the subject may stop to rest and resume walking or choose to terminate the test when he or she can walk no further. The investigator uses the modified Borg Scale (<xref ref-type="table" rid="table2-1099800411403918">Table 2</xref>
), which is a subjective numerical scale ranging from 0 to 10, and asks subjects to rate their perceived dyspnea and fatigue before and after the walk (<xref ref-type="bibr" rid="bibr4-1099800411403918">ATS, 2002</xref>; <xref ref-type="bibr" rid="bibr6-1099800411403918">Balady et al., 2010</xref>). The Borg scale also includes an activity intensity rating. Moreover, some 6MW protocols include measuring heart rate and oxygen saturation (using pulse oximetry) before, during, and after the test. Subject encouragement is known to increase the 6MW distance (<xref ref-type="bibr" rid="bibr30-1099800411403918">Guyatt et al., 1984</xref>); therefore, the <xref ref-type="bibr" rid="bibr4-1099800411403918">ATS (2002)</xref> recommends that if investigators use encouragement, they should follow a standardized protocol (e.g., voicing the same encouraging statement at the same intervals for each subject).</p>
<table-wrap id="table2-1099800411403918" position="float">
<label>Table 2.</label>
<caption>
<p>The Borg Scale</p>
</caption>
<graphic alternate-form-of="table2-1099800411403918" xlink:href="10.1177_1099800411403918-table2.tif"/>
<table>
<tbody>
<tr>
<td>0</td>
<td>Nothing at all</td>
</tr>
<tr>
<td>0.5</td>
<td>Very, very slight (just noticeable)</td>
</tr>
<tr>
<td>1</td>
<td>Very slight</td>
</tr>
<tr>
<td>2</td>
<td>Slight (light)</td>
</tr>
<tr>
<td>3</td>
<td>Moderate</td>
</tr>
<tr>
<td>4</td>
<td>Somewhat severe</td>
</tr>
<tr>
<td>5</td>
<td>Severe (heavy)</td>
</tr>
<tr>
<td>6</td>
<td>
</td>
</tr>
<tr>
<td>7</td>
<td>Very severe</td>
</tr>
<tr>
<td>8</td>
<td>
</td>
</tr>
<tr>
<td>9</td>
<td>
</td>
</tr>
<tr>
<td>10</td>
<td>Very, very severe (maximal)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1099800411403918">
<p>
<italic>Note:</italic> The Borg Scale is an exertion and dyspnea scale widely used during exercise stress testing and in cardiopulmonary rehabilitation. The higher the number, the greater the effort. From: <xref ref-type="bibr" rid="bibr4-1099800411403918">American Thoracic Society (2002)</xref>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The 6MW score is reported as the distance walked rounded to the nearest meter (despite the track’s length being measured in feet [100]). Group scores are reported as the mean distance ± the standard deviation. Mean distances vary across populations (<xref ref-type="table" rid="table3-1099800411403918">Table 3</xref>
). Normative values for the 6MW distance have not been established, but a review of several studies suggests that in healthy adults 6MW distances range from 386 to 800 meters (Alameri, Al-Majed, &amp; Al-Howaikan, 2009; <xref ref-type="bibr" rid="bibr27-1099800411403918">Gibbons, Fruchter, Sloan, &amp; Levy, 2001</xref>), and in patients with HF the reported baseline (preintervention) distances range from 169 to 400 meters (<xref ref-type="bibr" rid="bibr5-1099800411403918">Arslan et al., 2007</xref>; <xref ref-type="bibr" rid="bibr10-1099800411403918">Boxer, Wang, Walsh, Hager, &amp; Kenny, 2008</xref>), with the lowest distances measured in elderly, frail patients (<xref ref-type="bibr" rid="bibr10-1099800411403918">Boxer et al., 2008</xref>). All these ranges, however, should be interpreted with caution because high variability in 6MW distances has been attributed to a number of influencing factors, even in healthy individuals (<xref ref-type="bibr" rid="bibr22-1099800411403918">Enright, 2003</xref>; <xref ref-type="table" rid="table3-1099800411403918">Table 3</xref>).</p>
<table-wrap id="table3-1099800411403918" position="float">
<label>Table 3.</label>
<caption>
<p>Published Measured 6-Min Walk (6MW) Distances for Healthy Adults</p>
</caption>
<graphic alternate-form-of="table3-1099800411403918" xlink:href="10.1177_1099800411403918-table3.tif"/>
<table>
<thead>
<tr>
<th colspan="3">
</th>
<th colspan="2">6MWD (<italic>M</italic> ± <italic>SD</italic>) m</th>
</tr>
<tr>
<th>Reference</th>
<th>Country, Age in Years (y), <italic>N</italic>
</th>
<th>Independent Predictors</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alameri, Al-Majed, and Al-Howaikan (2009)</td>
<td>Saudi Arabia, 16–50 y, <italic>N</italic> = 238</td>
<td>Height, gender</td>
<td>430 ± 47 (<italic>n</italic> = 127)</td>
<td>386 ± 46 (<italic>n</italic> = 111)</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr17-1099800411403918">Camarri, Eastwood, Cecins, Thompson, and Jenkins (2006)</xref>
</td>
<td>Australia, 55–75 y, <italic>N</italic> = 70</td>
<td>Height, FEV1</td>
<td>690 ± 53 (<italic>n</italic> = 33)</td>
<td>631 ± 57 (<italic>n</italic> = 37)</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr27-1099800411403918">Gibbons, Fruchter, Sloan, and Levy (2001)</xref> <sup><xref ref-type="table-fn" rid="table-fn6-1099800411403918">a</xref>
</sup>
</td>
<td>Canada, 20–80 y, <italic>N</italic> = 86</td>
<td>Age, gender</td>
<td>20–40 y: 800 ± 83; 41–60 y: 671 ± 56; 61–80 y: 687 ± 89 (<italic>n</italic> = 41)</td>
<td>699 ± 37; 	670 ± 85; 583 ± 53 (<italic>n</italic> = 38)</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr38-1099800411403918">Iwama et al. (2009)</xref>
</td>
<td>Brazil, 13–84 y, <italic>N</italic> = 134</td>
<td>Age, gender</td>
<td>622 ± 80 (<italic>n</italic> = 61)</td>
<td>551 ± 74 (<italic>n</italic> = 73)</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr39-1099800411403918">Jenkins et al. (2009)</xref>
</td>
<td>Australia, 45–85 y, <italic>N</italic> = 109</td>
<td>NR</td>
<td>682 ± 73 (<italic>n</italic> = 48)</td>
<td>643 ± 70 (<italic>n</italic> = 61)</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr67-1099800411403918">Troosters, Gosselink, and Decramer (1999)</xref> <sup><xref ref-type="table-fn" rid="table-fn7-1099800411403918">b</xref>
</sup>
</td>
<td>Belgium, 50–85 y, <italic>N</italic> = 51</td>
<td>Height, age, weight, sex</td>
<td>
</td>
<td>631 ± 93 (average)</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr24-1099800411403918">Enright and Sherrill (1998)</xref> <sup><xref ref-type="table-fn" rid="table-fn8-1099800411403918">c</xref>
</sup>
</td>
<td>United States, 40–80 y, <italic>N</italic> = 488</td>
<td>Height, age, weight</td>
<td>576 ± NR (<italic>n</italic> = 117)</td>
<td>494 ± NR (<italic>n</italic> = 173)</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr57-1099800411403918">Poh, Eastwood, Cecins, Ho, and Jenkins (2006)</xref>
</td>
<td>Singapore, 45–85 y, <italic>N</italic> = 35</td>
<td>Height, age, weight, percentage predicted HR</td>
<td>586 ± 126 (<italic>n</italic> = 16)</td>
<td>538 ± 82 (<italic>n</italic> = 19)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1099800411403918">
<p>
<italic>Note:</italic> FEV1 = forced expiratory volume in 1 s; HR = heart rate; NR = not reported.</p>
</fn>
<fn id="table-fn6-1099800411403918">
<p>
<sup>a</sup> Data reported for 79 subjects.</p>
</fn>
<fn id="table-fn7-1099800411403918">
<p>
<sup>b</sup> Author reported group mean.</p>
</fn>
<fn id="table-fn8-1099800411403918">
<p>
<sup>c</sup> Subjects excluded as stepwise regression equations developed. Data are based on subset of healthy adults.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Investigators have commonly found that in patients with HF the 6MW distances correlate with age and that female patients walk shorter distances than males (<xref ref-type="bibr" rid="bibr1-1099800411403918">Alahdab et al., 2009</xref>; <xref ref-type="bibr" rid="bibr7-1099800411403918">Balashov et al., 2008</xref>; <xref ref-type="bibr" rid="bibr9-1099800411403918">Bittner et al., 1993</xref>; <xref ref-type="bibr" rid="bibr19-1099800411403918">Curtis, Rathore, Wang, &amp; Krumholz, 2004</xref>; <xref ref-type="bibr" rid="bibr35-1099800411403918">Howie-Esquivel &amp; Dracup, 2008</xref>). Generally, females have less muscle mass and smaller stature than males, which may contribute to a shorter stride. In addition, anemia is associated with functional decline, and its prevalence is higher in females than males in patients with HF (<xref ref-type="bibr" rid="bibr35-1099800411403918">Howie-Esquivel &amp; Dracup, 2008</xref>; <xref ref-type="bibr" rid="bibr43-1099800411403918">Kosiborod, Krumholz, Jones, Pitt, &amp; Spertus, 2008</xref>). In the elderly, the gradual reduction in skeletal muscle mass and strength influences gait speed and may be responsible for the decrease in 6MW distance (<xref ref-type="bibr" rid="bibr4-1099800411403918">ATS, 2002</xref>; <xref ref-type="bibr" rid="bibr23-1099800411403918">Enright et al., 2003</xref>). In healthy adults, age, gender, and weight are related to 6MW distance (<xref ref-type="bibr" rid="bibr22-1099800411403918">Enright, 2003</xref>; <xref ref-type="bibr" rid="bibr67-1099800411403918">Troosters, Gosselink, &amp; Decramer, 1999</xref>), and these variables are also significantly related to peak VO<sub>2</sub> (<xref ref-type="bibr" rid="bibr25-1099800411403918">Fleg et al., 2000</xref>). Others have proposed that in healthy adults leg length is an important covariate for the 6MW distance (<xref ref-type="bibr" rid="bibr38-1099800411403918">Iwama et al., 2009</xref>). The 6MW distances may differ significantly across racial and ethnic populations. For example, <xref ref-type="bibr" rid="bibr57-1099800411403918">Poh, Eastwood, Cecins, Ho, and Jenkins (2006)</xref> found that the actual 6MW distances measured in healthy Singaporean–Chinese adults (<italic>N</italic> = 35) were significantly less than predicted distances for healthy adults; however, the equations used for their predicted distances were derived from data from healthy Caucasian adults. This finding is consistent with those of others who have reported that the predicted distances derived from data on male walkers from the United States overestimated the 6MW distance for healthy male adults of Saudi descent (<xref ref-type="bibr" rid="bibr2-1099800411403918">Alameri et al., 2009</xref>) and underestimated the distance walked by Caucasian Australian males (<xref ref-type="bibr" rid="bibr39-1099800411403918">Jenkins et al., 2009</xref>). In sum, anthropomorphic and biological variables affect the 6MW distance, and investigators must therefore compare 6MW distances across studies cautiously and with regard to confounding variables.</p>
</sec>
<sec id="section4-1099800411403918">
<title>Reliability and Reproducibility of the 6MW Test</title>
<p>When investigators conduct the 6MW test inconsistently, a number of factors may contribute to poor reliability and reproducibility. For example, <xref ref-type="bibr" rid="bibr36-1099800411403918">Ingle (2009)</xref> suggested that differences in the corridor length or the number of turns in the walking course, as well as the dose of encouragement, may explain variability in reported 6MW distances. Although investigators often state that they used a 6MW protocol, few describe specifically how the protocol was standardized. Exceptions to this finding were studies in which the authors described how they used a script to give directions to the subjects, either avoided or standardized encouragement, and trained a single investigator to observe the 6MW test (<xref ref-type="bibr" rid="bibr35-1099800411403918">Howie-Esquivel &amp; Dracup, 2008</xref>; <xref ref-type="bibr" rid="bibr53-1099800411403918">O’Keefe, Lye, Donnelan, &amp; Carmichael, 1998</xref>).</p>
<p>Demers and colleagues (2001) found that the 6MW test was reliable and highly reproducible when conducted in a consistent manner. They compared 6MW distances measured at baseline, 18 weeks, and 43 weeks in subjects with HF (<italic>N =</italic> 768) and found evidence of good test–retest reliability (intraclass correlation coefficients = .90, .88, .91, respectively). Others, however, have reported increases in the 6MW distance over time in the absence of other indicators suggesting improved functional capacity. For example, Guyatt and colleagues (1985) found that as subjects underwent multiple 6MW tests, they walked increased distances. Others have attributed this finding to learning effects that occur with repeat testing (<xref ref-type="bibr" rid="bibr4-1099800411403918">ATS, 2002</xref>; <xref ref-type="bibr" rid="bibr15-1099800411403918">Butland et al., 1982</xref>; <xref ref-type="bibr" rid="bibr27-1099800411403918">Gibbons et al., 2001</xref>). To avoid measuring a learning effect, some investigators recommend using a screening walk for test familiarization (<xref ref-type="bibr" rid="bibr15-1099800411403918">Butland et al., 1982</xref>; <xref ref-type="bibr" rid="bibr27-1099800411403918">Gibbons et al., 2001</xref>; <xref ref-type="bibr" rid="bibr41-1099800411403918">Kervio, Carre, &amp; Ville, 2004</xref>) and taking the average (<xref ref-type="bibr" rid="bibr55-1099800411403918">Opasich et al., 1998</xref>, <xref ref-type="bibr" rid="bibr56-1099800411403918">2001</xref>) or the highest of replicate measures (<xref ref-type="bibr" rid="bibr4-1099800411403918">ATS, 2002</xref>).</p>
</sec>
<sec id="section5-1099800411403918">
<title>Validity of the 6MW Test</title>
<p>Researchers have shown that the 6MW distance correlates significantly with other measures of functional capacity used in HF patient populations, such as peak VO<sub>2</sub> (<italic>r</italic> = .64, <italic>p</italic> = .001, <xref ref-type="bibr" rid="bibr16-1099800411403918">Cahalin et al., 1996</xref>; <italic>r</italic> = .65, <italic>p</italic> = .011, <xref ref-type="bibr" rid="bibr63-1099800411403918">Roul et al., 1998</xref>). In addition, others found NYHA class to correlate inversely with the 6MW distance, showing that patients who were in higher functional classes (i.e., more symptomatic) walked shorter distances, although the strengths of these correlations were moderate, ranging from –.36 to –.46 (<xref ref-type="bibr" rid="bibr7-1099800411403918">Balashov et al., 2008</xref>; <xref ref-type="bibr" rid="bibr65-1099800411403918">Shah et al., 2001</xref>). For further discussion of heart failure studies that have used the 6MW test see <xref ref-type="table" rid="table4-1099800411403918">Table 4</xref>
.</p>
<table-wrap id="table4-1099800411403918" position="float">
<label>Table 4.</label>
<caption>
<p>Heart Failure Studies That Used the 6-Min Walk (6MW) Test</p>
</caption>
<graphic alternate-form-of="table4-1099800411403918" xlink:href="10.1177_1099800411403918-table4.tif"/>
<graphic alternate-form-of="table4-1099800411403918" xlink:href="10.1177_1099800411403918-table4a.tif"/>
<graphic alternate-form-of="table4-1099800411403918" xlink:href="10.1177_1099800411403918-table4b.tif"/>
<table>
<thead>
<tr>
<th>Study</th>
<th align="center">Ejection Fraction ± <italic>SD</italic>; Sample Size (% Male); Age (Years, Mean ± <italic>SD</italic>)</th>
<th>Use of the 6MW Test</th>
<th align="center">6MW Distance Baseline (<italic>m</italic>) Mean ± <italic>SD</italic>
</th>
<th>Correlation of 6MW Distance to Reference Criterion</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">Exercise intervention RCT</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr49-1099800411403918">McKelvie et al. (2002)</xref>, EXERT</td>
<td>Treatment: EF 28.2 ± 0.8; <italic>n</italic> = 90 (91%); age 66.1 ± 0.99. Control: EF 27.7 ± 0.9; <italic>n</italic> = 91 (87.9%); age 64.8 ± 1.1</td>
<td>Examine the effects of exercise training in patients with HF using the 6MW test as an outcome measure</td>
<td>Treatment: 434 ± 7 Control: 421 ± 8</td>
<td>Correlation not reported</td>
<td>Exercise training improved peak VO<sub>2</sub> and muscle strength but not the 6MW distance. Adherence to exercise training decreased over time</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr13-1099800411403918">Brubaker, Moore, Stewart, Wesley, and Kitzman (2009)</xref>
</td>
<td>Treatment: EF 32.1 ± 2.2; <italic>n</italic> = 30 (63.3%); age 70.4 ± 5.3. Control: EF 30.4 ± 8.8; <italic>n</italic> = 29 (69%); age 69.9 ± 6.3</td>
<td>Examine if 16 weeks of exercise training improves exercise capacity and other outcomes in elderly patients with HF and a low EF</td>
<td>Treatment: 444.4 ± 33.2<sup><xref ref-type="table-fn" rid="table-fn10-1099800411403918">a</xref>
</sup> Control: 410.8 ± 43.4</td>
<td>Correlation not reported</td>
<td>No improvement in 6MW distances following exercise training; peak VO<sub>2</sub> increased by 10% in only six patients</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr52-1099800411403918">O’Connor et al. (2009)</xref>, HF-ACTION</td>
<td>Treatment: EF 24.6 (20.0–30.0)<sup><xref ref-type="table-fn" rid="table-fn11-1099800411403918">b</xref></sup>; <italic>n</italic> = 1159 (70.1%); age 59.2 (51.2–67.8). Usual care: EF 24.9 (20.0–30.2); <italic>n</italic> = 1172 (73.2%); age 59.3 (51.1–68.2)</td>
<td>Test the efficacy and safety of aerobic exercise (36 supervised sessions followed by home training) of stable outpatients with HF</td>
<td>Treatment: 365.8 (296.3–436.2) Usual care: 373.2 (300.0-432.5)</td>
<td>Correlation not reported</td>
<td>6MW distance improved in exercise training group compared to usual care at 3 months; relationship not significant at 12 months. Adherence to exercise training protocol decreased over time</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr42-1099800411403918">Kitzman, Brubaker, Morgan, Stewart, and Little (2010)</xref>
</td>
<td>Treatment: EF 61 ± 5; <italic>n</italic> = 26 (23%); age 70 ± 6. Control: EF 60 ± 10; <italic>n</italic> = 20 (35%); age 69 ± 5</td>
<td>Examine the effects of a 16-week aerobic exercise training program on exercise intolerance and quality of life in patients with preserved ejection fraction</td>
<td>Treatment: 498 ± 75<sup><xref ref-type="table-fn" rid="table-fn10-1099800411403918">a</xref></sup>. Control: 471 ± 127</td>
<td>Correlation not reported</td>
<td>Exercise training improved 6MW distance in older patients with preserved EF</td>
</tr>
<tr>
<td>Mortality and hospitalization studies</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr9-1099800411403918">Bittner et al. (1993)</xref>, SOLVD</td>
<td>EF 30 ± 9; <italic>N</italic> = 898 (78%); age 59 ± 12</td>
<td>Examine use as prognostic indicator for hospitalization and mortality in patients with left ventricular dysfunction</td>
<td>374.3 ± 117.1</td>
<td>Correlation not reported</td>
<td>6MW test is a safe and independent predictor of mortality. Patients who walked &lt;300 m were at greatest risk for mortality and HF-related hospitalization</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr16-1099800411403918">Cahalin, Mathier, Semigran, Dec, and DiSalvo (1996)</xref>
</td>
<td>EF 20 ± 0.06; <italic>N</italic> = 45 (88.8%); age 49 ± 8</td>
<td>Assess functional capacity and predict mortality in patients with advanced HF</td>
<td>310 ± 100</td>
<td>Peak VO<sub>2</sub>: <italic>r</italic> = .64; <italic>p</italic> &lt; .001</td>
<td>6MW distance of &lt;300 m strongest predictor of peak VO<sub>2</sub>, mortality, and hospitalization for inotrope support within 6 months; peak VO<sub>2</sub> better predictor for long-term mortality</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr63-1099800411403918">Roul, German, and Bareiss (1998)</xref>
</td>
<td>EF 29.6 ± 13; <italic>N</italic> = 121 (48.7%); age 59 ± 11</td>
<td>Assess predictive value for mortality or hospitalization in a prospective study of patients with NYHA Class II and III HF</td>
<td>433 ± 108</td>
<td>Peak VO<sub>2</sub>: distance &lt;300 m. <italic>r</italic> = .65; <italic>p</italic> = .011</td>
<td>6MW test did not predict survival, but patients who walked &lt;300 m had a higher mortality</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr47-1099800411403918">Lucas et al. (1999)</xref>
</td>
<td>EF &lt; 35; <italic>N</italic> = 307 (78%); age 52 ± 13</td>
<td>Compare the 6MW distance and peak VO<sub>2</sub> (cycle ergometry) in potential transplant patients with advanced HF</td>
<td>393 ± 104</td>
<td>Peak VO<sub>2</sub> 10–20 ml/kg/min: <italic>r</italic> = .28; <italic>p</italic> not reported (<italic>n</italic> = 213)</td>
<td>6MW test is not a surrogate for peak VO<sub>2</sub> to assess aerobic capacity or prognosis for potential transplant candidates</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr68-1099800411403918">Zugck et al. (2000)</xref>
</td>
<td>EF 19 ± 7; <italic>N</italic> = 113 (79.6%); age 54 ± 12</td>
<td>Conduct serial comparisons between 6MW test and peak VO<sub>2</sub> in a defined group of patients with HF due to cardiomyopathy</td>
<td>466 ± 107</td>
<td>Peak VO<sub>2</sub> baseline: <italic>r</italic> = .68 (<italic>n</italic> = 113). Second visit: <italic>r</italic> = .71; <italic>p</italic> &lt; .001 (<italic>n</italic> = 28). Third visit: <italic>r</italic> = .74; <italic>p</italic> &lt; .001 (<italic>n</italic> = 14)</td>
<td>Serial 6MW testing may be a viable alternative to CPET to monitor an individual patient’s status or response to therapy</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr56-1099800411403918">Opasich et al. (2001)</xref>
</td>
<td>EF 26 ± 8; <italic>N</italic> = 315 (86.9%); age 53 ± 9</td>
<td>Assess prognostic value for peak VO<sub>2</sub>, NYHA class and survival; correlate indices of cardiac function in patients with NYHA Class II and III HF</td>
<td>396 ± 92</td>
<td>EF: <italic>r</italic> = .12; NS Peak VO<sub>2</sub>: <italic>r</italic> = .59; <italic>p</italic> &lt; .001. Anaerobic threshold: <italic>r</italic> = .54; <italic>p</italic> &lt; .001</td>
<td>6MW test does not predict mortality or substitute for peak VO<sub>2</sub> or NYHA class. The risk ratio for &lt;300 m was NS</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr65-1099800411403918">Shah et al. (2001)</xref>, FIRST database</td>
<td>EF 17 (14–20)<sup><xref ref-type="table-fn" rid="table-fn11-1099800411403918">b</xref></sup>; <italic>N</italic> = 365 (80%); age 64 (58–71)</td>
<td>Predict mortality and hospitalization in patients with NYHA Class IIIb or IV HF ineligible for transplantation; reassessed at 1 month; correlation between test performance and symptom score</td>
<td>218 (181-297)<sup><xref ref-type="table-fn" rid="table-fn11-1099800411403918">b</xref></sup>
</td>
<td>Composite symptom score for dyspnea, orthopnea, fatigue: <italic>r</italic> = –.385, <italic>p</italic> &lt; .001. NYHA class: <italic>r</italic> = –.468; <italic>p</italic> &lt; .001. Yale Dyspnea–Fatigue Index: <italic>r</italic> = –.485; <italic>p</italic> &lt; .001</td>
<td>Baseline and one-month 6MW distance significantly predicted mortality, hospitalization, and composite endpoint. Test may be useful to guide therapy in this very ill population</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr62-1099800411403918">Rostagno et al. (2003)</xref>
</td>
<td>Mild to moderate HF; <italic>N</italic> = 214 (55.6%); age 57.3 (29–70)</td>
<td>Assess prognostic value in patients with mild to moderate HF</td>
<td>NYHA Class I: 427 ± 71; NYHA Class II: 367 ± 90; NYHA Class II–IV: 242 ± 100</td>
<td>Peak VO<sub>2</sub>: <italic>r</italic> = .62; <italic>p</italic> &lt; .0001</td>
<td>36-month event-free survival was lower for patients who walked &lt;300 m. 6MW distance was a strong prognostic marker in univariate and multivariate analyses</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr19-1099800411403918">Curtis, Rathore, Wang, and Krumholz (2004)</xref>, DIG trial substudy</td>
<td>EF 34.7 ± 13.3; <italic>N</italic> = 541 (73.8%); age 64.5 ± 11.6</td>
<td>Assess prognostic value in stable outpatients with HF</td>
<td>335</td>
<td>Correlation not reported</td>
<td>6MW distance &lt;200 m was associated with increased symptoms and all-cause mortality risk</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr5-1099800411403918">Arslan et al. (2007)</xref>
</td>
<td>EF 35 ± .06; <italic>N</italic> = 43 (86%); age 62 ± 10</td>
<td>Predict mortality in stable outpatients with idiopathic dilated cardiomyopathy</td>
<td>400.2 ± 107.8</td>
<td>Correlation not reported</td>
<td>6MW distance ≤300 m and EF ≤30% was predictive of increased risk of mortality</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr35-1099800411403918">Howie-Esquivel and Dracup (2008)</xref>
</td>
<td>EF 43.2 ± 19; <italic>N</italic> = 44 (65.9%); age 59.6 ±18.6</td>
<td>Determine if oxygen saturation or 6MW distance predicts rehospitalization in patients admitted for acute HF</td>
<td>200.8 ± 111.6</td>
<td>Correlation not reported. Hazard ratio reported for 6MWT and readmission: HR 0.99, 95% CI 0.99–1.00, <italic>p</italic> = .06</td>
<td>No relationships between 6MW distance or oxygen saturation and rehospitalization. Women were significantly more anemic upon admission and walked shorter distances</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr1-1099800411403918">Alahdab, Mansour, Napan, and Stamos (2009)</xref>
</td>
<td>EF 29 ± 40; <italic>N</italic> = 200 (63.1%); age 55.7 ± 12.9</td>
<td>Predict mortality and rehospitalization in African American patients with acute HF</td>
<td>220 ± 130</td>
<td>Correlation not reported</td>
<td>6MW distance ≤200 m was the strongest predictor of mortality and rehospitalization</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr29-1099800411403918">Guazzi, Dickstein, Vicenzi, and Arena (2009)</xref>
</td>
<td>EF 36.3 ± 11.4; <italic>N</italic> = 253 (78.6%); age 61.9 ± 10.1</td>
<td>Compare CPET-derived variables to the 6MW test predicting mortality in patients with HF (low and preserved EF) referred for cardiopulmonary exercise lab</td>
<td>350 ± 92.8</td>
<td>No significant association with peak VO<sub>2</sub>, anaerobic threshold, and EF even when using a cutoff of ≤300 m; CPET-derived ventilatory variables were prognostic for all 6MW distances</td>
<td>6MW distances &lt;300 m did not predict mortality in univariate or multivariate analysis as a continuous or dichotomous variable</td>
</tr>
<tr>
<td>Noninterventional trials</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr31-1099800411403918">Guyatt et al. (1988)</xref>
</td>
<td>EF not reported; <italic>N</italic> = 20 (90%); age 63 ± 11</td>
<td>Serve as outcome variable to determine the efficacy of Digoxin in sinus rhythm</td>
<td>NR</td>
<td>Higher NYHA class, jugular venous distention &gt;6 cm, + S<sub>3</sub> were associated with 6MW distance &lt;300 m</td>
<td>Variables associated with a response to digoxin were also indicative of increased severity of HF</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr45-1099800411403918">Lipkin, Scriven, Crake, and Poole-Wilson (1986)</xref>
</td>
<td>EF not reported; <italic>N</italic> = 26 (76.9%); age 58 (36–68)<sup><xref ref-type="table-fn" rid="table-fn11-1099800411403918">b</xref>
</sup>
</td>
<td>Assess validity of 6MW test as a measure of exercise capacity in patients with NYHA Class II and III HF</td>
<td>NYHYA Class II: 562 ± 30; Class III: 402 ± 30<sup><xref ref-type="table-fn" rid="table-fn12-1099800411403918">c</xref>
</sup>
</td>
<td>Correlation not reported</td>
<td>Curvilinear relationship between peak VO<sub>2</sub> and 6MW distance</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr53-1099800411403918">O’Keefe, Lye, Donnelan, and Carmichael (1998)</xref>
</td>
<td>EF not reported; <italic>N</italic> = 60 (37%); age 81 (74–92)<sup><xref ref-type="table-fn" rid="table-fn11-1099800411403918">b
</xref>
</sup>
</td>
<td>Examine the responsiveness to change and reproducibility of the 6MW test in patients with HF in a geriatric outpatient clinic</td>
<td>238.8 ± 51.5</td>
<td>Baseline dyspnea scale on CHQ: <italic>r</italic> = –.58 (<italic>p</italic> not reported); Responsiveness coefficient (RC) = 1.73</td>
<td>6MWT was more sensitive for detecting deterioration than improvement in elderly HF patients</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr21-1099800411403918">Demers, McKelvie, Negassa, and Yusuf (2001)</xref>, substudy of RESOLVD</td>
<td>EF 27 ± 10; <italic>N</italic> = 768 (83%); age 63 ± 11</td>
<td>Evaluate the reliability, validity, and responsiveness of 6MW test in stable NYHA Class II–IV patients with EF &lt;40%</td>
<td>381 ± 84</td>
<td>NYHA: <italic>r</italic> = –.43; <italic>p</italic> = .001. QoL: <italic>r</italic> = –.26; <italic>p</italic> = .0001</td>
<td>QoL most responsive to change; NYHA and 6MW test less responsive to change but comparable</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr41-1099800411403918">Kervio, Carre, and Ville (2004)</xref>
</td>
<td>EF &lt; 40; Healthy <italic>n</italic> = 12 (50%); HF drugs optimized (HFD) <italic>n</italic> = 14 (35.7%); HF drugs optimized/CRT (HFP) <italic>n</italic> = 19 (29.4%); age 65.0 ± 1.4</td>
<td>Assess cardiorespiratory parameters during 6MW test in patients with chronic HF optimized on drug therapy and patients with chronic HF optimized on drug therapy with CRT</td>
<td>Healthy: 564.4 ± 20.1; HFD: 452.6 ± 18.7; HFP: 379.6 ± 20.6</td>
<td>TV/breathing frequency: <italic>r</italic> = .45, <italic>p</italic> &lt; .01</td>
<td>6MW test corresponded to intense exercise (90% peak VO<sub>2</sub>) in both HF groups. Each HF group was characterized by a specific adaptive ventilation response</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr37-1099800411403918">Ingle et al. (2005)</xref>
</td>
<td>EF &lt; 40; <italic>N</italic> = 1077 (74.5%); age &gt; 60</td>
<td>Assess sensitivity to change of self-perceived symptoms of HF</td>
<td>285 ± 122<sup><xref ref-type="table-fn" rid="table-fn13-1099800411403918">d</xref>
</sup>
</td>
<td>Symptom severity: <italic>r</italic> = –.75; <italic>p</italic> = .00001</td>
<td>Strong correlation between change in symptom severity and change in 6MW distance</td>
</tr>
<tr>
<td>
<xref ref-type="bibr" rid="bibr48-1099800411403918">Maldonado-Martín et al. (2006)</xref>
</td>
<td>EF 50 ± 21.4; <italic>N</italic> = 97 (40.2%); age 69.1 ± 5.6</td>
<td>Correlate the 6MW test with peak VO<sub>2</sub> and VT in elderly patients with HF with a low (<italic>n</italic> = 50) and preserved (<italic>n</italic> = 47) EF</td>
<td>438 ± 111.2</td>
<td>Peak VO<sub>2</sub>: <italic>r</italic> = .23; <italic>p</italic> = .04. VT: <italic>r</italic> = .74; <italic>p</italic> &lt; .001</td>
<td>Weak correlation between peak VO<sub>2</sub> and 6MW distance does not predict functional capacity in older patients with HF</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-1099800411403918">
<p>
<italic>Note:</italic> The reader is also referred to the reviews by <xref ref-type="bibr" rid="bibr54-1099800411403918">Olsson, Swedberg, Clark, Witte, and Cleland (2005)</xref> and <xref ref-type="bibr" rid="bibr58-1099800411403918">Pollentier et al. (2010)</xref>. CHQ = Chronic Heart Failure Questionnaire; CPET = cardiopulmonary exercise stress testing; CRT = cardiac resynchronization therapy; DIG = Digitalis Investigation Group; EF = ejection fraction; EXERT = Exercise Rehabilitation Trial; FIRST = Flolan International Randomized Survival Trial; HF = heart failure; HF-ACTION = Heart Failure—A Controlled Trial Investigating Outcomes of Exercise Training; NS = not significant; NYHA = New York Heart Association; QoL = quality of life; RCT = randomized controlled trial; RESOLVD = Randomized Evaluation of Strategies for Left Ventricular Dysfunction studies; SOLVD = Studies of Left Ventricular Dysfunction; TV = tidal volume; VO<sub>2</sub> = oxygen consumption; VT = ventilatory threshold.</p>
</fn>
<fn id="table-fn10-1099800411403918">
<p>
<sup>a</sup> Original data reported in feet; converted to meters by current authors.</p>
</fn>
<fn id="table-fn11-1099800411403918">
<p>
<sup>b</sup> Data reported as a range.</p>
</fn>
<fn id="table-fn12-1099800411403918">
<p>
<sup>c</sup> data reported as mean ± standard error</p>
</fn>
<fn id="table-fn13-1099800411403918">
<p>
<sup>d</sup> No change group</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-1099800411403918">
<title>Predictive Value of the 6MW Test in HF Outcomes</title>
<p>The 6MW distance has been assessed in several studies, including large randomized clinical trials, to determine its ability to predict adverse outcomes (e.g., hospitalization, mortality). Analysis of data from the SOLVD registry showed that every 120-meter decrease in the 6MW distance was associated with a 160% increase in the likelihood of hospitalization (<xref ref-type="bibr" rid="bibr9-1099800411403918">Bittner et al., 1993</xref>). Others found that a 6MW distance &lt;200 m was a significant and independent predictor of hospitalization (<xref ref-type="bibr" rid="bibr1-1099800411403918">Alahdab et al., 2009</xref>; <xref ref-type="bibr" rid="bibr19-1099800411403918">Curtis et al., 2004</xref>). In contrast to the above findings, <xref ref-type="bibr" rid="bibr35-1099800411403918">Howie-Esquivel and Dracup (2008)</xref> found no significant relationship between the predischarge 6MW distance and the risk for rehospitalization; however, this study included predominantly patients assigned to NYHA Classes I or II, and the timeframe for determining rehospitalization was limited to 3 months.</p>
<p>Investigators have extensively examined the relationship between low 6MW distances and mortality in HF. The results are equivocal with regard to proposed cutoff scores indicative of increased mortality risk. Patients enrolled in SOLVD who walked &lt;350 m had a significantly increased mortality risk of 10% (<italic>p</italic> &lt; .01) compared to patients who walked greater distances and their associated mortality risk of 3% (<xref ref-type="bibr" rid="bibr9-1099800411403918">Bittner et al., 1993</xref>). <xref ref-type="bibr" rid="bibr5-1099800411403918">Arslan et al. (2007)</xref> found that a 6MW distance less than 300 m predicted mortality (79% vs. 7%; adjusted hazard ratio 2.38; <italic>p</italic> &lt; .001) in a 2-year prospective study of patients with cardiomyopathy. Others have proposed a 200 m cutoff (<xref ref-type="bibr" rid="bibr1-1099800411403918">Alahdab et al., 2009</xref>; <xref ref-type="bibr" rid="bibr19-1099800411403918">Curtis et al., 2004</xref>). For example, patients enrolled in the Digitalis Investigation Group trial had significantly higher all-cause mortality (59%, <italic>p</italic> &lt; .001) over the 32-month follow-up if their baseline 6MW distance was &lt;200 m (<xref ref-type="bibr" rid="bibr19-1099800411403918">Curtis et al., 2004</xref>). In African American patients, <xref ref-type="bibr" rid="bibr1-1099800411403918">Alahdab et al. (2009)</xref> found that a 6MW distance of &lt;200 m was the strongest independent predictor of all-cause mortality (adjusted HR 2.14, 95% CI 1.20–3.81, <italic>p</italic> = .01). Regardless of EF, patients were enrolled in this study if they met the Framingham criteria for HF diagnosis. Despite the above evidence that a low 6MW distance can be used to predict mortality, neither <xref ref-type="bibr" rid="bibr29-1099800411403918">Guazzi, Dickstein, Vicenzi, and Arena (2009)</xref> nor <xref ref-type="bibr" rid="bibr56-1099800411403918">Opasich et al. (2001)</xref> found a statistically significant relationship between mortality risk and the 6MW distance.</p>
</sec>
<sec id="section7-1099800411403918">
<title>Responsiveness of the 6MW Distance to HF Therapies</title>
<p>Although valid and reliable tests are essential, in the setting of HF, it is also important that tests be able to detect significant clinical changes over time, particularly in response to interventions. Although investigators may expect the distance walked to increase when patients receive pharmacological therapies, several randomized multicenter clinical trials have not supported this hypothesis, including RESOLVD (<xref ref-type="bibr" rid="bibr21-1099800411403918">Demers et al., 2001</xref>) and a dose–response trial of bucindolol (<xref ref-type="bibr" rid="bibr12-1099800411403918">Bristow et al., 1994</xref>), though both those studies reported their protocol for standardized 6MW tests. For example, in RESOLVD the 6MW distance did not improve over 12–43 weeks in an investigation of core pharmacological therapies including β-adrenergic receptor blockers (e.g., metoprolol), angiotensin-converting enzyme inhibitors (e.g., enalapril), and angiotensin receptor blockers (e.g., candesartan). The failure of these agents to improve the 6MW distance in most studies could reflect differences in study design, sample size, and characteristics; the inability of the treatment to affect symptoms; or the inclusion of patients with mild symptoms.</p>
<p>In a systematic review of 46 trials, <xref ref-type="bibr" rid="bibr54-1099800411403918">Olsson, Swedberg, Clark, Witte, and Cleland (2005)</xref> examined the ability of the 6MW test to detect an increased distance walked in congruence with other measures expected to show improvement with HF interventions (39 randomized, blinded drug trials; 6 device/cardiac resynchronization trials; and 1 exercise-intervention trial). In 30 of these trials, patients’ 6MW distances did not improve significantly despite those patients having received one of these interventions. In 89% of cases, however, the 6MW distance increased significantly when HF symptoms (e.g., dyspnea, fatigue) improved following therapy (<xref ref-type="bibr" rid="bibr54-1099800411403918">Olsson et al., 2005</xref>). <xref ref-type="bibr" rid="bibr37-1099800411403918">Ingle et al. (2005</xref>; <italic>n</italic> = 516) showed that the 6MW distance also changed in concordance with deterioration and worsening of HF symptoms. In pharmacological trials and in a limited number of device trials, however, it remains inconclusive whether significant clinical changes can be detected using the 6MW test (<xref ref-type="bibr" rid="bibr54-1099800411403918">Olsson et al., 2005</xref>). Investigators may not find improvements in the 6MW distance in intervention trials because of the issues previously noted, such as differences in study design or sample (e.g., inclusion of patients with mild symptoms) and the inability of the treatment to affect symptoms. The lack of improvement in the 6MW distance may also be due to unique reasons, such as baseline characteristics of each sample (e.g., including or excluding patients with comorbidities) or nonadherence of patients to the intervention (e.g., exercise).</p>
</sec>
<sec id="section8-1099800411403918">
<title>Limitations of the 6MW Test in HF</title>
<p>The 6MW test is an attractive alternative to CPET because it is feasible, simple, and affordable; however, investigators who plan to use the 6MW test must acknowledge its limitations. Findings regarding the ability of the 6MW test to detect clinically significant changes in drug and device trials are inconclusive, meaning that the 6MW distance should not be the sole outcome measure in studies of HF interventions. Also, there are no established normative data on 6MW distances for patients with HF. Readers should consider the interpretation of published 6MW data along with the sample characteristics, including age, gender, race/ethnicity, height, weight, and NYHA class. Many published studies included few patients who were female (<xref ref-type="bibr" rid="bibr7-1099800411403918">Balashov et al., 2008</xref>) or of a minority race/ethnicity (<xref ref-type="bibr" rid="bibr60-1099800411403918">Rasekaba, Lee, Naughton, Williams, &amp; Holland, 2009</xref>); therefore, these findings may not be generalizable to all HF populations. In addition, few patients in NYHA Class IV were enrolled in these trials; therefore, data about functional capacity are limited for patients with severe HF.</p>
</sec>
<sec id="section9-1099800411403918">
<title>Recommendations for Using the 6MW Test</title>
<sec id="section10-1099800411403918">
<title>Using a 6MW Test Protocol</title>
<p>To avoid introducing measurement error related to the conduct of the test, investigators must follow a standardized 6MW protocol. <xref ref-type="bibr" rid="bibr58-1099800411403918">Pollentier et al. (2010)</xref> reviewed 14 studies to evaluate the implementation quality of the 6MW test and found that the inconsistent use of 6MW protocols was a major threat to the integrity of many studies. A 6MW protocol should include using scripts to give directions, giving encouragement in a standardized manner, limiting eye contact with the subject during the walk, and walking behind, not next to, the subject during the test (<xref ref-type="bibr" rid="bibr4-1099800411403918">ATS, 2002</xref>; <xref ref-type="bibr" rid="bibr30-1099800411403918">Guyatt et al., 1984</xref>). If the investigator uses encouragement inconsistently, subject motivation may be a confounding factor. In terms of encouragement, the <xref ref-type="bibr" rid="bibr4-1099800411403918">ATS (2002)</xref> recommends using standardized phrases delivered at 1-min intervals. Finally, if there are multiple observers administering the test, investigators should report indices of agreement (intercorrelation coefficient [ICC] or percentage agreement).</p>
<p>When determining the frequency of multiple 6MW tests, investigators should also consider the implications of learning effects associated with repeat testing. When feasible, the first 6MW test should be considered test familiarization. <xref ref-type="bibr" rid="bibr61-1099800411403918">Reybrouck (2003)</xref> cautions against using data from any studies where the investigators did not allow a training session because the reported distances may not reflect patients’ abilities, especially for patients who initially underperformed to avoid experiencing dyspnea or fatigue. There are different thoughts about the appropriate interval between baseline 6MW tests. Waiting more than 24 hr between the baseline tests is not advised, as the <xref ref-type="bibr" rid="bibr4-1099800411403918">ATS (2002)</xref> reported differences of up to 17% when 6MW tests were repeated one day apart. Instead, they recommend waiting 1 hr between 6MW tests and reporting the highest 6MW distance as the patient’s baseline. However, many of the studies we reviewed used a single baseline measure. The use of repeated 6MW tests may be of greater importance when evaluating the effects of an intervention in studies where a practice effect may confound the results.</p>
<p>When using the 6MW test in the HF population, investigators may have to digress from the ATS protocol to avoid adverse events. For example, during evaluation of NYHA Class IV or pretransplant patients, it may be advisable to monitor the heart rhythm and follow behind the patient with a monitor/defibrillator. Patients with HF may fatigue easily and either be unable to complete two 6MW tests 1 hr apart or refuse the test; therefore, it may be necessary to oversample. Also, patients with HF frequently have multiple comorbidities, such as diabetes or pulmonary hypertension, which may require additional physiological monitoring before, during and after the walk.</p>
</sec>
<sec id="section11-1099800411403918">
<title>Analyzing and Reporting the 6MW Data</title>
<p>Investigators should report mean distances with the standard deviation (in meters), the percentage change in distance with replicate measures, and an index of agreement when there are multiple observers. Others have determined clinically meaningful cutoff scores for the 6MW (e.g., distances less than 200, 300, and 350 meters; <xref ref-type="bibr" rid="bibr1-1099800411403918">Alahdab et al., 2009</xref>; <xref ref-type="bibr" rid="bibr5-1099800411403918">Arslan et al., 2007</xref>; <xref ref-type="bibr" rid="bibr9-1099800411403918">Bittner et al., 1993</xref>; <xref ref-type="bibr" rid="bibr19-1099800411403918">Curtis et al., 2004</xref>). Investigators may encounter statistical limitations, such as decreased statistical power, when analyzing the 6MW distance as a categorical variable (e.g., distance less than or greater than a determined cutoff) rather than as a continuous variable. Determining cutoff scores for clinically meaningful outcomes (such as mortality and rehospitalization), however, yields important information. Therefore, investigators may want to examine their results using the 6MW distance as both a categorical and continuous variable.</p>
<p>In addition, investigators should report any patient characteristics that may be related to the 6MW distance (e.g., age, gender, race/ethnicity, height, weight, NYHA class). As these variables are known to be 6MW distance confounders, it is important to control for these variables statistically as well. Reporting the number and characteristics of patients who stopped to rest or who did not complete the 6MW test also provides important clinical information. Investigators should use the Borg Scale to rate dyspnea and fatigue before and after the 6MW test to give information about HF symptoms during the walk (<xref ref-type="bibr" rid="bibr6-1099800411403918">Balady et al., 2010</xref>). Finally, there have been few studies about how the 6MW distance correlates with biomarkers (e.g., hemoglobin, B-type natriuretic peptide). Such investigations may provide important information about physiological mechanisms that are activated when there are changes in functional capacity with HF.</p>
<p>Although investigators do not collectively use a standardized method to report the responsiveness of the 6MW test to therapies, <xref ref-type="bibr" rid="bibr33-1099800411403918">Guyatt, Walter, and Norman (1987)</xref> recommended reporting the responsiveness coefficient (RC) and interpreting changes in the 6MW distance. <xref ref-type="bibr" rid="bibr51-1099800411403918">Norman, Wyrwich, and Patrick (2007)</xref> detailed the calculation of RCs. The coefficient reflects the magnitude of change that is clinically important (<xref ref-type="bibr" rid="bibr33-1099800411403918">Guyatt et al., 1987</xref>). Following recommendations by Guyatt and colleagues, others have reported 30 m as the minimally/clinically important difference (<xref ref-type="bibr" rid="bibr31-1099800411403918">Guyatt et al., 1988</xref>; <xref ref-type="bibr" rid="bibr53-1099800411403918">O’Keefe et al., 1998</xref>). The RC has implications for determining sample size; a higher RC indicates that fewer patients are needed to detect the minimally important change in response to an intervention (i.e., devices, medications, or behavioral interventions). Few authors, however, have reported the RC in publications or have provided details about effect sizes, which is important information for determining required sample sizes for future studies.</p>
</sec>
</sec>
<sec id="section12-1099800411403918">
<title>Conclusion</title>
<p>When the 6MW test is conducted according to a standardized protocol, it is a reliable and valid measure of functional capacity but does not substitute for the value of all CPET-derived parameters. There is insufficient evidence to support using the 6MW distance to detect meaningful clinical changes in drug and device trials in patients with HF. Due to its simplicity, however, the 6MW test is an excellent method to use in conjunction with other methods in HF research and may be particularly useful for identifying those at increased risk for hospitalization and mortality in some HF populations.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors acknowledge Dr. Mariann R. Piano for her intellectual contribution and Kevin Grandfield for his editorial assiatnce.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-1099800411403918">
<p>The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1099800411403918">
<p>The authors received no financial support for the research and/or authorship of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alahdab</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Mansour</surname>
<given-names>I. N.</given-names>
</name>
<name>
<surname>Napan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stamos</surname>
<given-names>T. D.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Six minute walk test predicts long-term all-cause mortality and heart failure rehospitalization in African-American patients hospitalized with acute decompensated heart failure</article-title>. <source>Journal of Cardiac Failure</source>, <volume>15</volume>, <fpage>130</fpage>–<lpage>135</lpage>.</citation>
</ref>
<ref id="bibr2-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alameri</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Al-Majed</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Al-Howaikan</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Six-min walk test in a healthy adult Arab population</article-title>. <source>Respiratory Medicine</source>, <volume>103</volume>, <fpage>1041</fpage>–<lpage>1046</lpage>.</citation>
</ref>
<ref id="bibr3-1099800411403918">
<citation citation-type="book">
<collab collab-type="author">American College of Sports Medicine</collab>. (<year>2008</year>). <source>ACSMs guidelines for exercise testing and prescription</source>
(<edition>7th ed</edition>.). <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Wolters Kluwer</publisher-name>.</citation>
</ref>
<ref id="bibr4-1099800411403918">
<citation citation-type="journal">
<collab collab-type="author">American Thoracic Society</collab>. (<year>2002</year>). <article-title>Guidelines for the six-minute walk test</article-title>. <source>American Journal of Respiratory Critical Care Medicine</source>, <volume>138</volume>, <fpage>291</fpage>–<lpage>298</lpage>.</citation>
</ref>
<ref id="bibr5-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arslan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Erol</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Gundogdu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sevimli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aksakal</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Senocak</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Alp</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Prognostic value of 6-minute walk test</article-title>. <source>Texas Heart Institute Journal</source>, <volume>34</volume>, <fpage>166</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr6-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balady</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Arena</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sietsema</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Coke</surname>
<given-names>L.</given-names>
</name>
<name><surname>Flether</surname><given-names>G. F.</given-names>
</name>
<name>
<surname>… Milani</surname>
<given-names>R. V.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Clinician’s guide to cardiopulmonary exercise testing in adults: A scientific statement from the American Heart Association</article-title>. <source>Circulation</source>, <volume>122</volume>, <fpage>191</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr7-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balashov</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Savard</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Houde</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Frenette</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ducharme</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>… Pilote</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Percent predicted value for the 6-minute walk test: Using norm-referenced equations to characterize severity in persons with CHF</article-title>. <source>Journal of Cardiac Failure</source>, <volume>14</volume>, <fpage>75</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr8-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bangdiwala</surname>
<given-names>S. I.</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Bourassa</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Friesinger</surname>
<given-names>G. C. Ghali, J. K.</given-names>
</name>
<name>
<surname>Yusuf</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Studies of left ventricular dysfunction registry: Rationale, design, methods and description of baseline characteristics</article-title>. <source>American Journal of Cardiology</source>, <volume>70</volume>, <fpage>347</fpage>–<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr9-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bittner</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Yusuf</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>McIntyre</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Bangdiwala</surname>
<given-names>S. I.</given-names>
</name>
<name>
<surname>… Bourassa</surname>
<given-names>M. G.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD investigators</article-title>. <source>Journal of the American Medical Association</source>, <volume>270</volume>, <fpage>1702</fpage>–<lpage>1707</lpage>.</citation>
</ref>
<ref id="bibr10-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boxer</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hager</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kenny</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>The utility of the six-minute walk test as a measure of frailty in older adults with heart failure</article-title>. <source>American Journal of Geriatric Cardiology</source>, <volume>17</volume>, <fpage>7</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr11-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braunschweig</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Linde</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Adamson</surname>
<given-names>P. B.</given-names>
</name>
<name>
<surname>Magalski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Erdmann</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kjellstrom</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Continuous central haemodynamic measurements during the six minute walk test and daily life in patients with chronic heart failure</article-title>. <source>European Journal of Heart Failure</source>, <volume>11</volume>, <fpage>594</fpage>–<lpage>601</lpage>.</citation>
</ref>
<ref id="bibr12-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bristow</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>O’Connell</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Leatherman</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kantrowitz</surname>
<given-names>N. E.</given-names>
</name>
<name>
<surname>… Anderson</surname>
<given-names>J. L.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Dose-response of chronic B-blocker treatment in heart failure from either idiopathic or ischemic cardiomyopathy</article-title>. <source>Circulation</source>, <volume>89</volume>, <fpage>1632</fpage>–<lpage>1642</lpage>.</citation>
</ref>
<ref id="bibr13-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brubaker</surname>
<given-names>P. H.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>K. P.</given-names>
</name>
<name>
<surname>Wesley</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Kitzman</surname>
<given-names>D. W.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Endurance exercise training in older patients with heart failure: Results from a randomized, controlled, single-blind trial</article-title>. <source>Journal of the American Geriatrics Society</source>, <volume>57</volume>, <fpage>1982</fpage>–<lpage>1989</lpage>.</citation>
</ref>
<ref id="bibr14-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brunelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Refax</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Monteverde</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Borri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salati</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fianchini</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Stair climbing test predicts cardiopulmonary complications after lung resection</article-title>. <source>Chest</source>, <volume>121</volume>, <fpage>1106</fpage>–<lpage>1110</lpage>.</citation>
</ref>
<ref id="bibr15-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butland</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>E. R.</given-names>
</name>
<name>
<surname>Woodcock</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Geddes</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>1982</year>). <article-title>Two, six, and 12-minute walking tests in respiratory disease</article-title>. <source>British Medical Journal</source>, <volume>284</volume>, <fpage>1607</fpage>–<lpage>1608</lpage>.</citation>
</ref>
<ref id="bibr16-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cahalin</surname>
<given-names>L. P.</given-names>
</name>
<name>
<surname>Mathier</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Semigran</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Dec</surname>
<given-names>G. W.</given-names>
</name>
<name>
<surname>DiSalvo</surname>
<given-names>T. G.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>The six minute walk test predicts peak oxygen uptake and survival of patients with advanced heart failure</article-title>. <source>Chest</source>, <volume>100</volume>, <fpage>325</fpage>–<lpage>332</lpage>.</citation>
</ref>
<ref id="bibr17-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camarri</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Eastwood</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Cecins</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Six minute walk distance in healthy subjects aged 55-75 years</article-title>. <source>Respiratory Medicine</source>, <volume>100</volume>, <fpage>658</fpage>–<lpage>665</lpage>.</citation>
</ref>
<ref id="bibr18-1099800411403918">
<citation citation-type="book">
<collab collab-type="author">Criteria Committee of the New York Heart Association</collab>. (<year>1994</year>). <source>Nomenclature and criteria for diagnosis of diseases of the heart and great vessels</source> (<edition>9th ed</edition>.). <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Little Brown</publisher-name>.</citation>
</ref>
<ref id="bibr19-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curtis</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Rathore</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Krumholz</surname>
<given-names>H. M.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>The association of 6-minute walk performance and outcomes in stable outpatients with heart failure</article-title>. <source>Journal of Cardiac Failure</source>, <volume>10</volume>, <fpage>9</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr20-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delahaye</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cohen-Solal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Faraggi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Czitrom</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Foult</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Daou</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>… Le Guludec</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Comparison of left ventricular responses to the six-minute walk test, stair climbing, and maximal upright bicycle exercise in patients with congestive heart failure due to idiopathic dilated cardiomyopathy</article-title>. <source>American Journal of Cardiology</source>, <volume>80</volume>, <fpage>65</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr21-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demers</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McKelvie</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Negassa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yusuf</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Reliability, validity and responsiveness of the six-minute walk test in patients with heart failure</article-title>. <source>American Heart Journal</source>, <volume>142</volume>, <fpage>678</fpage>–<lpage>703</lpage>.</citation>
</ref>
<ref id="bibr22-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enright</surname>
<given-names>P. L.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>The six-minute walk test</article-title>. <source>Respiratory Care</source>, <volume>48</volume>, <fpage>783</fpage>–<lpage>785</lpage>.</citation>
</ref>
<ref id="bibr23-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enright</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>McBurnie</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Bittner</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tracy</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>McNamara</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>A. B.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>The 6-min walk test: A quick measure of functional status in elderly adults</article-title>. <source>Chest</source>, <volume>123</volume>, <fpage>387</fpage>–<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr24-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enright</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Sherrill</surname>
<given-names>D. L.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Reference equations for the six-minute walk in healthy adults</article-title>. <source>American Journal of Respiratory Critical Care Medicine</source>, <volume>158</volume>, <fpage>1384</fpage>–<lpage>1387</lpage>.</citation>
</ref>
<ref id="bibr25-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fleg</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Pina</surname>
<given-names>I. L.</given-names>
</name>
<name>
<surname>Balady</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Chaitman</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Fletcher</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lavie</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>… Bazzarre</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Assessment of functional capacity in clinical and research applications: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association</article-title>. <source>Circulation</source>, <volume>102</volume>, <fpage>1591</fpage>–<lpage>1597</lpage>.</citation>
</ref>
<ref id="bibr26-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frankenstein</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Remppis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schellberg</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sigg</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nelles</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>… Zugck</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Gender and age related predictive value of walk test in heart failure: Do anthropometrics matter in clinical practice?</article-title> <source>International Journal of Cardiology</source>, <volume>127</volume>, <fpage>331</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr27-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibbons</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Fruchter</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sloan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>R. D.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years</article-title>. <source>Journal of Cardiopulmonary Rehabilitation</source>, <volume>21</volume>, <fpage>87</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr28-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldman</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>E. F.</given-names>
</name>
<name>
<surname>Loscalzo</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>1981</year>). <article-title>Comparative reproducibility and validity of systems for assessing cardiovascular function class: Advantages of a new specific activity scale</article-title>. <source>Circulation</source>, <volume>64</volume>, <fpage>1127</fpage>–<lpage>1234</lpage>.</citation>
</ref>
<ref id="bibr29-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guazzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dickstein</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vicenzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Arena</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>6 minute walk test and cardiopulmonary exercise testing in chronic heart failure: A comparative analysis on clinical and prognostic insights</article-title>. <source>Circulation</source>, <volume>109</volume>, <fpage>549</fpage>–<lpage>555</lpage>.</citation>
</ref>
<ref id="bibr30-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guyatt</surname>
<given-names>G. H.</given-names>
</name>
<name>
<surname>Pugsley</surname>
<given-names>S. O.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>L. B.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>N. L.</given-names>
</name>
<name>
<surname>… Taylor</surname>
<given-names>D. W.</given-names>
</name>
</person-group> (<year>1984</year>). <article-title>Effect of encouragement on walking test performance</article-title>. <source>Thorax</source>, <volume>39</volume>, <fpage>818</fpage>–<lpage>822</lpage>.</citation>
</ref>
<ref id="bibr31-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guyatt</surname>
<given-names>G. H.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Fallen</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>Tihal</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rideout</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Halcrow</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>… Taylor</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>1988</year>). <article-title>A controlled trial of digoxin in congestive heart failure</article-title>. <source>American Journal of Cardiology</source>, <volume>61</volume>, <fpage>371</fpage>–<lpage>375</lpage>.</citation>
</ref>
<ref id="bibr32-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guyatt</surname>
<given-names>G. H.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Fallen</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>Pugsley</surname>
<given-names>S. O.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>L. B.</given-names>
</name>
</person-group> (<year>1985</year>). <article-title>The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure</article-title>. <source>Canadian Medical Association Journal</source>, <volume>132</volume>, <fpage>919</fpage>–<lpage>923</lpage>.</citation>
</ref>
<ref id="bibr33-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guyatt</surname>
<given-names>G. H.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Norman</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>1987</year>). <article-title>Measuring change over time—Assessing the usefulness of evaluative instruments</article-title>. <source>Journal of Chronic Disability</source>, <volume>40</volume>, <fpage>171</fpage>–<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr34-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendrican</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>McKelvie</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>McCartney</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pogue</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Teo</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Yusuf</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Functional capacity in patients with congestive heart failure</article-title>. <source>Journal of Cardiac Failure</source>, <volume>6</volume>, <fpage>212</fpage>–<lpage>219</lpage>.</citation>
</ref>
<ref id="bibr35-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howie-Esquivel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dracup</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Does oxygen saturation or distance walked predict rehospitalization in heart failure?</article-title> <source>Journal of Cardiovascular Nursing</source>, <volume>23</volume>, <fpage>349</fpage>–<lpage>356</lpage>.</citation>
</ref>
<ref id="bibr36-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingle</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>A review of the six-minute walk test: Its implication as a self-administered assessment tool</article-title>. <source>European Journal of Cardiovascular Nursing</source>, <volume>8</volume>, <fpage>232</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr37-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingle</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shelton</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Rigby</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Nabb</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Cleland</surname>
<given-names>J. G.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure</article-title>. <source>European Heart Journal</source>, <volume>26</volume>, <fpage>1742</fpage>–<lpage>1751</lpage>.</citation>
</ref>
<ref id="bibr38-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwama</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>G. N.</given-names>
</name>
<name>
<surname>Shima</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tanni</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Godoy</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Dourado</surname>
<given-names>V. Z.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>The six-minute walk test and body weight-walk distance product in healthy Brazilian subjects</article-title>. <source>Brazilian Journal of Medical and Biological Research</source>, <volume>42</volume>, <fpage>1080</fpage>–<lpage>1085</lpage>.</citation>
</ref>
<ref id="bibr39-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jenkins</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cecins</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Camarri</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Eastwood</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Regression equations to predict the 6-minute walk distance in middle-aged and elderly adults</article-title>. <source>Physiotherapy Theory Practice</source>, <volume>25</volume>, <fpage>516</fpage>–<lpage>522</lpage>.</citation>
</ref>
<ref id="bibr40-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kervio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Carre</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ville</surname>
<given-names>N. S.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Reliability and intensity of the six-minute walk test in healthy elderly subjects</article-title>. <source>Medicine and Science in Sports Exercise</source>, <volume>35</volume>, <fpage>169</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr41-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kervio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ville</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Leclercq</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Daubert</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Carre</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Cardiorespiratory adaptations during the six-minute walk test in chronic heart failure patients</article-title>. <source>European Journal of Cardiovascular, Prevention, and Rehabilitation</source>, <volume>11</volume>, <fpage>171</fpage>–<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr42-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitzman</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Brubaker</surname>
<given-names>P. H.</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>K. P.</given-names>
</name>
<name>
<surname>Little</surname>
<given-names>W. C.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Exercise training in older patients with heart failure and preserved ejection fraction: A randomized, controlled, single-blind trial</article-title>. <source>Circulation. Heart Failure</source>, <volume>3</volume>, <fpage>659</fpage>–<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr43-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosiborod</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Krumholz</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>P. G.</given-names>
</name>
<name>
<surname>Pitt</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Spertus</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>The relationship between anemia, change in hematocrit over time and change in health status in patients with heart failure after myocardial infarction</article-title>. <source>Journal of Cardiac Failure</source>, <volume>14</volume>, <fpage>27</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr44-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindenfeld</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Boehmer</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Ezekowitz</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Giventz</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>… Walsh</surname>
<given-names>M. N.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Executive summary: HFSA 2010 comprehensive heart failure practice guidelines</article-title>. <source>Journal of Cardiac Failure</source>, <volume>16</volume>, <fpage>475</fpage>–<lpage>539</lpage>.</citation>
</ref>
<ref id="bibr45-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipkin</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Scriven</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Crake</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Poole-Wilson</surname>
<given-names>P.A.</given-names>
</name>
</person-group> (<year>1986</year>). <article-title>Six minute walking test for assessing exercise capacity in chronic heart failure</article-title>. <source>British Medical Journal</source>, <volume>292</volume>, <fpage>653</fpage>–<lpage>655</lpage>.</citation>
</ref>
<ref id="bibr46-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lloyd-Jones</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Carnethon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Simone</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>… Wylie-Rosett</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Heart disease and stroke statistics 2010 update: A report from the American Heart Association</article-title>. <source>Circulation</source>, <volume>121</volume>, <fpage>e46</fpage>–<lpage>e215</lpage>.</citation>
</ref>
<ref id="bibr47-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Warner Stevenson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hartley</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Walden</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>… Eagen-Bensten</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>The 6-min walk and peak oxygen consumption in advanced heart failure: Aerobic capacity and survival</article-title>. <source>American Heart Journal</source>, <volume>138</volume>, <fpage>618</fpage>–<lpage>624</lpage>.</citation>
</ref>
<ref id="bibr48-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maldonado-Martín</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brubaker</surname>
<given-names>P. H.</given-names>
</name>
<name>
<surname>Kaminsky</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>K. P.</given-names>
</name>
<name>
<surname>Kitzman</surname>
<given-names>D. W.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>The relationship of a 6-min walk to VO(2 peak) and VT in older heart failure patients</article-title>. <source>Medicine and Science in Sports and Exercise</source>, <volume>38</volume>, <fpage>1047</fpage>–<lpage>1053</lpage>.</citation>
</ref>
<ref id="bibr49-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKelvie</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Teo</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>McCartney</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Humen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Montague</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>… Yusuf</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Effects of exercise training in patients with heart failure: The exercise rehabilitation trial (EXERT)</article-title>. <source>American Heart Journal</source>, <volume>144</volume>, <fpage>23</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr50-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morales</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mendez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Agarrado</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ortega</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fernandez-Guerra</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>… Burgos</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>A shuttle walk test for assessment of functional capacity in chronic heart failure</article-title>. <source>American Heart Journal</source>, <volume>138</volume>, <fpage>291</fpage>–<lpage>298</lpage>.</citation>
</ref>
<ref id="bibr51-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norman</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Wyrwich</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Patrick</surname>
<given-names>D. L.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>The mathematical relationship among different forms of responsiveness coefficients</article-title>. <source>Quality of Life Research</source>, <volume>16</volume>, <fpage>815</fpage>–<lpage>822</lpage>.</citation>
</ref>
<ref id="bibr52-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Connor</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Whellan</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Keteyian</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>… Pina</surname>
<given-names>I. L.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial</article-title>. <source>Journal of the American Medical Association</source>, <volume>301</volume>, <fpage>1439</fpage>–<lpage>1450</lpage>.</citation>
</ref>
<ref id="bibr53-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Keefe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lye</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Donnelan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Carmichael</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients</article-title>. <source>Heart</source>, <volume>80</volume>, <fpage>377</fpage>–<lpage>382</lpage>.</citation>
</ref>
<ref id="bibr54-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olsson</surname>
<given-names>L. G.</given-names>
</name>
<name>
<surname>Swedberg</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Witte</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Cleland</surname>
<given-names>J. G.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized blinded intervention trials of chronic heart failure: A systematic review</article-title>. <source>European Heart Journal</source>, <volume>26</volume>, <fpage>778</fpage>–<lpage>793</lpage>.</citation>
</ref>
<ref id="bibr55-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Opasich</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pinna</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Mazza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Febo</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>P. G.</given-names>
</name>
<name>
<surname>Capomolla</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>… Tavazzi</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Reproducibility of the six-minute walking test in patients with chronic congestive heart failure: Practical implications</article-title>. <source>American Journal of Cardiology</source>, <volume>81</volume>, <fpage>1497</fpage>–<lpage>1500</lpage>.</citation>
</ref>
<ref id="bibr56-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Opasich</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pinna</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Mazza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Febo</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>P. G.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Six-minute walking performance with moderate to severe heart failure: Is it a useful indicator in clinical practice?</article-title> <source>European Heart Journal</source>, <volume>22</volume>, <fpage>488</fpage>–<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr57-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Eastwood</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Cecins</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>K. T.</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>S. C.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Six-minute walk distance in healthy Singaporeans cannot be predicted using reference equations from Caucasian populations</article-title>. <source>Respirology</source>, <volume>11</volume>, <fpage>211</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr58-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pollentier</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Irons</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Benedetto</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Dibenedetto</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Loton</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Seyler</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>… Newton</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Examination of the six minute walk test to determine functional capacity in people with chronic heart failure: A systematic review</article-title>. <source>Cardiopulmonary Physical Therapy Journal</source>, <volume>21</volume>, <fpage>13</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr59-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raphael</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Briscoe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Whinett</surname>
<given-names>Z. I.</given-names>
</name>
<name>
<surname>Manisty</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>… Francis</surname>
<given-names>D. P.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure</article-title>. <source>Heart</source>, <volume>93</volume>, <fpage>476</fpage>–<lpage>482</lpage>.</citation>
</ref>
<ref id="bibr60-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rasekaba</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Naughton</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>A. E.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>The six-minute walk test: A useful metric for the cardiopulmonary patient</article-title>. <source>Internal Medicine Journal</source>, <volume>39</volume>, <fpage>495</fpage>–<lpage>501</lpage>.</citation>
</ref>
<ref id="bibr61-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reybrouck</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Clinical usefulness and limitations of the 6-minute walk test in patients with cardiovascular or pulmonary disease</article-title>. <source>Chest</source>, <volume>123</volume>, <fpage>325</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr62-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rostagno</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Olivo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Comeglio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Boddi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Banchelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Galanti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gensini</surname>
<given-names>G. F.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Prognostic value of 6-minute walk corridor in patients with mild to moderate heart failure: Comparison to other methods of functional evaluation</article-title>. <source>European Journal of Heart Failure</source>, <volume>5</volume>, <fpage>247</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr63-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roul</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>German</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bareiss</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Does the 6 minute walk test predict the prognosis in patients with NYHA Class II and III heart failure?</article-title> <source>American Heart Journal</source>, <volume>136</volume>, <fpage>449</fpage>–<lpage>457</lpage>.</citation>
</ref>
<ref id="bibr64-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schocken</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Fonarow</surname>
<given-names>G. C.</given-names>
</name>
<name>
<surname>Krumholz</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mensah</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>… Hong</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Prevention of heart failure: A scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group</article-title>. <source>Circulation</source>, <volume>107</volume>, <fpage>2544</fpage>–<lpage>2465</lpage>.</citation>
</ref>
<ref id="bibr65-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Hasselblad</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gheorghiade</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>K. F.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Swedberg</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Califf</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>O’Connor</surname>
<given-names>C. M.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy</article-title>. <source>American Journal of Cardiology</source>, <volume>88</volume>, <fpage>987</fpage>–<lpage>993</lpage>.</citation>
</ref>
<ref id="bibr66-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hardman</surname>
<given-names>A. E.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Development of a shuttle walking test of disability in patients with chronic airway obstruction</article-title>. <source>Thorax</source>, <volume>47</volume>, <fpage>1019</fpage>–<lpage>1024</lpage>.</citation>
</ref>
<ref id="bibr67-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Troosters</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gosselink</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Decramer</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Six minute walking distance in healthy elderly subjects</article-title>. <source>European Respiratory Journal</source>, <volume>14</volume>, <fpage>270</fpage>–<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr68-1099800411403918">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zugck</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kruger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Durr</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gerber</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Haunsetter</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hornig</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>… Haass</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Is the 6-minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy?</article-title> <source>European Heart Journal</source>, <volume>21</volume>, <fpage>540</fpage>–<lpage>549</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>